

Appl. No. : 10/026,066
Filed : December 7, 2001

AMENDMENTS TO THE CLAIMS

1. (Currently amended) ~~An~~ A composition suitable for adoptive administration to an animal, comprising a first isolated T cell in a pharmaceutically acceptable formulation, the formulation comprising a pharmaceutically acceptable carrier, adjuvant, diluent, or excipient, wherein said T cell expresses ~~expressing~~ a T cell receptor specific for an MHC-peptide complex comprising a first housekeeping epitope, wherein the housekeeping epitope is derived from a first antigen associated with a first target cell.

2. (Currently amended) ~~A~~ The composition of Claim 1, comprising a T cell clone comprising the said isolated T cell of claim 1.

3. (Currently amended) ~~A~~ The composition of Claim 1, comprising a polyclonal population of T cells comprising the said isolated T cell of claim 1.

4. (Currently amended) The composition of Claim 1, wherein said T cell of claim 1 is produced by an in vitro immunization.

5. (Currently amended) The composition of Claim 1, wherein said T cell of claim 1 is isolated from an immunized animal.

6-28 (Cancelled)

29. (Currently amended) The composition of Claim 1, wherein the first target cell is a neoplastic cell.

30. (Currently amended) The composition of Claim 1, wherein the first antigen is a tumor associated antigen.

31. (Currently amended) The composition of Claim 30, wherein the tumor associated antigen is a cancer-testis antigen.

32. (Currently amended) The composition of Claim 30, wherein the tumor associated antigen is selected from the group consisting of NY-ESO, PSMA, SSX-2 and PRAME.

33. (Currently amended) The composition of Claim 30, wherein the tumor associated antigen is a melanoma differentiation antigen.

34. (Currently amended) The composition of Claim 33, wherein the melanoma differentiation antigen is selected from the group consisting of tyrosinase, MelanA, and gp100.

Appl. No. : 10/026,066
Filed : December 7, 2001

35. (Currently amended) The composition ~~isolated T cell~~ of Claim 1, wherein the MHC is A2.

36. (Currently amended) The composition ~~isolated T cell~~ of Claim 1, wherein the MHC is selected from the group consisting of A1, A3, A24, B7 and B8.

37. (New) The composition of Claim 1, further comprising a second isolated T cell wherein the second T cell expresses a T cell receptor specific for an MHC-peptide complex comprising a second housekeeping epitope, wherein the housekeeping epitope is derived from a second antigen associated with a second target cell.

38. (New) The composition of Claim 37, wherein said first antigen and said second antigen are the same.

39. (New) The composition of Claim 37, wherein said first target cell and said second target cell are the same.

40. (New) The composition of Claim 1, comprising from about 10^5 to about 10^8 T cells.

41. (New) The composition of Claim 1, comprising from about 10^8 to about 10^{11} T cells.

42. (New) A composition suitable for adoptive administration to an animal, comprising at least a first and a second isolated T cell population, wherein said first population expresses a T cell receptor specific for an MHC-peptide complex comprising a first housekeeping epitope derived from a first antigen associated with a first target cell, and wherein said second population expresses a T cell receptor specific for an MHC-peptide complex comprising a second housekeeping epitope derived from a second antigen associated with a second target cell.